Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-04-16

FDA Approved: RUFINAMIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Rufinamide (Hikma Pharmaceuticals USA Inc.) under ANDA204988, signaling an approved addition or change to the ex…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rufinamide (Rufinamide)

Snippet

SUPPL AP for RUFINAMIDE (RUFINAMIDE)